142167-38-2

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-4-chlorosalicylic acid is used as an intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs and enhance the properties of existing ones.
Used in Agrochemical Industry:
In the agrochemical industry, 5-Bromo-4-chlorosalicylic acid serves as an intermediate in the production of agrochemicals, aiding in the creation of effective solutions for agricultural applications.
Used in Dye and Pigment Manufacturing:
5-Bromo-4-chlorosalicylic acid is utilized in the manufacturing of dyes and pigments, where its chemical properties contribute to the creation of vibrant and stable colorants for various uses.
Used in Organic Chemical Production:
5-Bromo-4-chlorosalicylic acid is also employed in the production of other organic chemicals, showcasing its versatility and importance in the chemical industry.
Used in Antimicrobial Agent Development:
5-Bromo-4-chlorosalicylic acid is used in the development of antimicrobial agents due to its antimicrobial properties, making it a valuable component in the formulation of products designed to combat microbial growth.

InChI:InChI=1/C7H4BrClO3/c8-4-1-3(7(11)12)6(10)2-5(4)9/h1-2,10H,(H,11,12)

Upstream product

• 5106-98-9 4-chlorosalicylic acid 
• 55488-81-8 methyl 5-bromo-4-chloro-2-hydroxybenzoate 

Downstream Products

• 142167-39-3 2-(5-bromo-4-chloro-2-hydroxybenzoyl)pyridine 
• 343948-94-7 2-Acetoxy-5-bromo-4-chloro-benzoic acid 
• 142167-44-0 4,5-dibromo-2-hydroxybenzoic acid 
• 1070892-80-6 5-bromo-2-(3-tert-butoxycarbonyl-propoxy)-4-chloro-benzoic acid 3-tert-butoxycarbonyl-propyl ester 
• 1070892-87-3 5-bromo-4-chloro-2-hydroxy-N-(2-methoxy-phenyl)-N-methyl-benzamide 
• 55488-81-8 methyl 5-bromo-4-chloro-2-hydroxybenzoate 
• 1070892-82-8 5-bromo-2-(3-tert-butoxycarbonyl-propoxy)-4-chloro-benzoic acid 2-trimethylsilanyl-ethyl ester 
• 1070892-81-7 5-bromo-2-(3-tert-butoxycarbonyl-propoxy)-4-chloro-benzoic acid 
• 1070892-88-4 5-bromo-4-chloro-2-(3-cyano-propoxy)-N-(2-methoxy-phenyl)-N-methyl-benzamide 
• 1026449-11-5 5-bromo-4-chloro-2-hydroxybenzamide 
• 162270-27-1 2-(5-bromo-4-chloro-α-cyano-2-methoxymethoxybenzyl)-3-methoxymethoxypyridine 
• 162271-18-3 2-(5-bromo-4-chloro-2-methoxymethoxybenzoyl)-3-methoxymethoxypyridine 
• 162267-42-7 (5-Bromo-4-chloro-2-hydroxy-phenyl)-(3-hydroxy-pyridin-2-yl)-methanone O-tert-butyl-oxime 
• 162269-62-7 2-(5-bromo-4-chloro-2-hydroxybenzoyl)-3-hydroxypyridine 

Relevant academic research and scientific papers

INHIBITORS OF THE BCL6 BTB DOMAIN PROTEIN-PROTEIN INTERACTION AND USES THEREOF

The present application relates to compounds of Formula I (I) or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, to compositions comprising these compounds or pharmaceutically acceptable salts, solvates and/or prodrugs thereof, and various uses in the treatment of diseases, disorders or conditions that are treatable by inhibiting interactions with BCL6 BTB, such as cancer.

Big catkin willow acids compounds and medical use

The invention discloses a AMPK agonist activity with salicylic acid compound and its preparation method and medical use, it is the structural formula of the formula (I) compound of formula, its pharmaceutically acceptable salt or prodrug or solvate. The structure of the invention of formula (I) compound of formula activated AMPK, therefore can be used for preparing the prevention or treatment of AMPK mediated diseases.

Novel salicylanilides from 4,5-dihalogenated salicylic acids: Synthesis, antimicrobial activity and cytotoxicity

Salicylanilides have proved their activity against tuberculosis (TB). One weak electron-withdrawing substituent is favored at the salicylic part, specially Cl or Br atoms at positions 4 or 5. On the other hand, the antimycobacterial activity of salicylanilides is negatively affected when a strong electron-withdrawing substituent ([sbnd]NO2) is present at the same positions. Herein we describe the synthesis and characterization of novel salicylanilides possessing two weak electron-withdrawing groups (halogen atoms) at their salicylic part and compare their antitubercular activity with their monohalogenated analogues. All dihalogenated derivatives proved to possess antitubercular activity at a very narrow micromolar range (MIC?=?1–4?μM), similar with their most active monohalogenated analogues. More importantly, the most active final molecules were further screened against multidrug resistant strains and found to inhibit their growth at the range of 0.5–4?μM.

Process development of potassium channel opener, TCV-295, based on convenient ring formation of 2H-1,3-benzoxazine and selective N-oxidation of the pyridyl moiety

An efficient process for potassium channel opener, TCV-295, based on a novel and convenient 4-(2-pyridyl)-2H-1,3-benzoxazine ring formation from o-hydroxybenzoylpyridine by the NH4I/piperidine/2,2-dimethoxypropane system and the following selective pyridine-N-oxidation using dimethyldioxirane, has been developed. Additionally, the combination reagent of ammonium halide and sec- or tert- amine conveniently converted o-hydroxyphenyl arylketones with several ketones (or benzaldehyde) to various novel 4-aryl-2H-1,3-benzoxazines.

Synthesis and biological activity of novel 1,3-benzoxazine derivatives as K+ channel openers

A new series of 1,3-benzoxazine derivatives with a 2-pyridine 1-oxide group at C4 was designed to explore novel K+ channel openers. Synthesis was carried out by using a palladium(0)-catalyzed carbon-carbon bond formation reaction of imino-triflates with organozinc reagents and via a new one-pot 1,3-benzoxazine skeleton formation reaction of benzoylpyridines. The compounds were tested for vasorelaxant activity in tetraethylammonium chloride (TEA) and BaCl2-induced and high KCl-induced contraction of rat aorta to identify potential K+ channel openers, and also for oral hypotensive effects in spontaneously hypertensive rats. An electron- withdrawing group with the proper shape at C6 and a methyl or halogens group at C7 of the 1,3-benzoxazine nucleus were required for the development of optimal vasorelaxant and hypotensive activity. In particular, 2-(6-bromo-7- chloro-2,2-dimethyl-2H-1,3-benzoxazin-4-yl)pyridine 1-oxide (71) showed more potent vasorelaxant activity (EC50=0.14 μM) against TEA and BaCL2- induced contraction and longer-lasting hypotensive effects than cromakalim (1).

1,3-benzoxazine derivatives, their production and use

A new compound of the formula: STR1 wherein STR2 is an optionally substituted benzene ring; R1 is a carbocyclic or heterocyclic group which is linked to the 4-position of the 1,3-benzoxazine ring through a carbon-carbon bond, a hydrocarbon resi